| Project/Area Number |
15K13748
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Bio-related chemistry
|
|---|
| Research Institution | Kyushu Institute of Technology |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
UTO Yoshihiro 徳島大学, ソシオテクノサイエンス研究部, 教授 (20304553)
|
|---|
| Research Collaborator |
ISLAM Md. Monirul
ESAKI Yugo
TAKENAKA Fuminori
MINEMATSU Hiroki
SHINOZAKI Shingo
KAJIMA Atsuhito
HAMANAKA Hisashi
KUROSE Yui
SHINJO Akina
SAMESHIMA Shino
TANAKA Masami
TAKEUCHI Ryusuke
WAKAHARA Daiki
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 4本鎖DNA / 環状ナフタレンジイミド / 抗癌剤 / テロメアDNA / 4本鎖DNAをターゲットとした抗がん剤 / ヒトテロメアDNA / c-kit / c-myc / ナフタレンジイミド / 抗がん剤 |
|---|
| Outline of Final Research Achievements |
To develop an anti-cancer drug without side-effect, a series of cyclic naphthalene diimide (cNDI) derivatives was synthesized and studied their interactions with teraplex DNAs (tDNA) using spectrophotometric and isothermal titration calorimetric technique with telomerase and growth inhibition assay of cancer cell. cNDIs carrying none-aromatic moiety have a high preference for tDNA over duplex one (dsDNA). However, their binding affinity and stabilization effect for tDNA is not enough for use of anticancer drug. On the other hand, cNDIs carrying aromatic moiety have high binding affinity for tDNA and, however, their preference for tDNA over dsDNA is not enough because of their interaction for dsDNA. The affinity of cNDIs for tDNA was correlated with telomerase and growth inhibition assay of cancer cell. These results suggested that cNDI open new concept to design anti-cancer drug with diminished side effect.
|
